Hofseth Biocare ASA: COMPLETED ANNUAL GENERAL MEETING
April 28 2023 - 8:09AM
Hofseth Biocare ASA: COMPLETED ANNUAL GENERAL MEETING
Hofseth BioCare ASA held its Annual General
Meeting on 28 April 2023. 253,351,609 shares, amounting to 64.13
per cent of the share capital, were represent in the meeting or by
proxy. All proposals were resolved as presented in the notice
issued on 13 April 2023.
The minutes from the Annual General Meeting are
attached.
For further information, please contact:Jon Olav
Ødegård, CEO at HBCPhone: +47 936 32 966E-mail:
joo@hofsethbiocare.no
About HBC: HBC is a Norwegian consumer and pet health ingredient
supplier and an incubator for new pharmaceutical drug leads.
Research is ongoing to identify the individual elements within its
ingredients that modulate inflammation and the immune response
with pre-clinical studies ongoing in multiple clinics and
university research labs. Lead clinical and pre-clinical candidates
are focused on developing an oral treatment for inflammatory
disease driven by eosinophils (a type of white blood cell).
Clinical trial work with the oil is ongoing to ameliorate lung
inflammation in eosinophilic asthma and COPD ("smokers lung") as
well as in COVID. Other leads are focused on the protection of the
Gastro- Intestinal (GI) system against inflammation (including
ulcerative colitis and the orphan condition necrotising
enterocolitis) and using a special formula of soluble protein
hydrolysate (SPH also known as ProGo®) as a Medical Food to help
treat IBD, and for Iron Deficiency Anemia.
The company is founded on the core values of sustainability,
optimal utilization of natural resources and full traceability.
Through an innovative hydrolysis technology, HBC can preserve the
quality of the lipids, proteins and calcium from fresh salmon
off-cuts. HBC's headquarters are in Ålesund, Norway with branches
in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto.
HBC is listed on Oslo Børs with ticker "HBC". More information
about HBC at hofsethbiocare.com
This information is subject to the disclosure
requirements pursuant to Section 5-12 the Norwegian Securities
Trading Act
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Dec 2024 to Jan 2025
Hofseth Biocare Asa (LSE:0Q6H)
Historical Stock Chart
From Jan 2024 to Jan 2025